Why It Matters

Elanco Animal Health faces a regulatory bottleneck: innovative feed additives that could improve livestock efficiency and reduce environmental impact are trapped in lengthy drug approval processes—even though they aren’t drugs. The company is pushing Congress to create a faster pathway through the Innovative FEED Act, which would reclassify certain feed ingredients as food additives. Success would let U.S. producers access new technologies faster and help Elanco compete globally. With bipartisan support and desperate farmers needing efficiency gains, Elanco’s strategy targets a legislative moment where regulatory modernization is viewed as critical to agricultural competitiveness.

By the Numbers

Elanco Animal Health Inc. spent $505,000 on lobbying in Q3 2025 through its in-house team. This continues the company’s substantial federal advocacy presence, totaling approximately $11.5 million across 165 filings since 2003.

Elanco’s lobbying spend targets two priorities with significant congressional momentum: the Innovative FEED Act and Farm Bill animal health provisions. The company’s team includes John Marshall Stewart, who worked for Rep. David Rouzer (R-NC), a senior House Agriculture Committee member.

The company deployed six in-house lobbyists, including two new additions: Robin Jeanine Bowen, who joined after work with the Corn Refiners Association, and Caroline T. Ghazal.

This Q3 filing represents a strategic shift. Historically, Elanco maintained extensive external lobbying firms alongside its in-house team, including Bockorny Group Inc. ($3.24 million, 2005-2025). The company has consolidated to an in-house-only approach, streamlining operations while maintaining focus on the Innovative FEED Act.

The Agenda

Elanco is heavily focused on the Innovative FEED Act of 2025 (H.R. 2203/S. 1906), which would create streamlined FDA pathways for feed additives. The bill reclassifies "zootechnical animal food substances"—ingredients improving efficiency and reducing environmental impact—from drug approval to faster food additive processes.

The company is also engaged on Farm Bill negotiations, specifically "various titles supporting animal health-related topics," plus tariff barriers, supply chain resilience, and international standards.

Broader Context

Congress is aggressively pursuing animal health modernization as disease threats intensify. The Innovative FEED Act, backed by over 190 organizations, gained momentum after the Reagan-Udall Foundation’s July 2025 analysis called current regulations "out-of-date" and "overly risk-averse."

Disease preparedness has become urgent with African Swine Fever’s nearly 350 new outbreaks in 2025 and H5N1 avian influenza threatening cattle. The 2025 Farm Bill appropriated $10 million annually for disease preparedness.

Meanwhile, livestock producers face economic pressure with USDA projecting record $467 billion production expenses in 2025, making them receptive to efficiency-boosting products.

Between The Lines

The Innovative FEED Act, introduced by Rep. Kim Schrier (D-WA), has bipartisan backing. House Agriculture Committee members like Rep. Tracey Mann (R-KS) are pushing increased National Animal Health Laboratory Network funding.

The bipartisan Senate Veterinary Medicine Caucus, expanded by Sens. Cindy Hyde-Smith (R-MS) and Amy Klobuchar (D-MN), provides industry engagement forums. The SAFE Act of 2025 would enable regionalized trade agreements preventing disease outbreaks from shutting entire export markets.

Competitive Landscape

Elanco faces well-resourced competitors pursuing identical priorities, strengthening collective advocacy power. Zoetis Inc. lobbies on Farm Bill provisions, while Tyson Foods Inc. engages on feed additives. The Animal Health Institute also lobbies on the Innovative FEED Act.

This industry alignment amplifies advocacy power by demonstrating broad stakeholder consensus rather than narrow special interests, increasing legislative success probability.

The Bottom Line

The legislative environment favors Elanco’s priorities, with recent hearings emphasizing disease preparedness and regulatory modernization. Industry alignment—with competitors like Zoetis pursuing identical goals—strengthens the reform case. Elanco’s advocacy represents standard industry priorities rather than controversial positions, suggesting reasonable legislative prospects.

Spot something wrong? Report an issue with this article